Matches in SemOpenAlex for { <https://semopenalex.org/work/W4375846719> ?p ?o ?g. }
Showing items 1 to 61 of
61
with 100 items per page.
- W4375846719 abstract "Abstract Aims Bruton’s tyrosine kinase inhibitors (BTKIs), including first-generation ibrutinib, second-generation acalabrutinib, and zanubrutinib may have certain mechanisms of action (MOAs) related to adverse effects (AEs) on the cardiovascular system. We aimed to evaluate the cardiac AEs of BTKIs reported to the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) and to compare the differences in cardiovascular toxicity of ibrutinib, acalabrutinib, and zanubrutinib. Methods Only primary suspect drugs from the FAERS database were extracted from January 2013 to December 2022 across all indications of FDA-approved BTKIs. Disproportionality was measured by reporting odds ratios (RORs) and information components (ICs). An additional disproportionality analysis was also performed from January 2020 to December 2022. Results A total of 10,353 cases involving ibrutinib, acalabrutinib and zanubrutinib were included. Ibrutinib was significantly associated with the incidence of cerebrovascular accidents, myocardial infarction and other thrombotic events. Acalabrutinib was associated with new signals, including cardiac failure, ventricular extrasystoles, pulmonary edema and angina pectoris, and hypertension and myocardial infarction were found in additional analyses. Furthermore, acalabrutinib was characterized by a much earlier onset of cardiovascular events. Only atrial fibrillation was associated with zanubrutinib use. Acalabrutinib and zanubrutinib had lower ROR values for cardiac AEs, and fewer signals for these two drugs compared with ibrutinib. Conclusion This study indicated that new AEs were not clearly noted on the label for acalabrutinib. It is suggested that the cardiovascular risks of BTKIs remain a concern and worth attention as next-generation BTKIs are discovered and developed." @default.
- W4375846719 created "2023-05-10" @default.
- W4375846719 creator A5030684730 @default.
- W4375846719 creator A5051198814 @default.
- W4375846719 creator A5057790274 @default.
- W4375846719 creator A5066716873 @default.
- W4375846719 creator A5071605787 @default.
- W4375846719 creator A5074850827 @default.
- W4375846719 date "2023-05-07" @default.
- W4375846719 modified "2023-10-18" @default.
- W4375846719 title "Cardiovascular Events of Bruton’s Tyrosine Kinase Inhibitors: A Real-World Study Based on the FDA Adverse Events Reporting System (FAERS) Database" @default.
- W4375846719 doi "https://doi.org/10.22541/au.168347169.98648154/v1" @default.
- W4375846719 hasPublicationYear "2023" @default.
- W4375846719 type Work @default.
- W4375846719 citedByCount "0" @default.
- W4375846719 crossrefType "posted-content" @default.
- W4375846719 hasAuthorship W4375846719A5030684730 @default.
- W4375846719 hasAuthorship W4375846719A5051198814 @default.
- W4375846719 hasAuthorship W4375846719A5057790274 @default.
- W4375846719 hasAuthorship W4375846719A5066716873 @default.
- W4375846719 hasAuthorship W4375846719A5071605787 @default.
- W4375846719 hasAuthorship W4375846719A5074850827 @default.
- W4375846719 hasBestOaLocation W43758467191 @default.
- W4375846719 hasConcept C126322002 @default.
- W4375846719 hasConcept C197934379 @default.
- W4375846719 hasConcept C2777105317 @default.
- W4375846719 hasConcept C2777938653 @default.
- W4375846719 hasConcept C2778461978 @default.
- W4375846719 hasConcept C2779878957 @default.
- W4375846719 hasConcept C41008148 @default.
- W4375846719 hasConcept C500558357 @default.
- W4375846719 hasConcept C71924100 @default.
- W4375846719 hasConcept C77088390 @default.
- W4375846719 hasConcept C98274493 @default.
- W4375846719 hasConceptScore W4375846719C126322002 @default.
- W4375846719 hasConceptScore W4375846719C197934379 @default.
- W4375846719 hasConceptScore W4375846719C2777105317 @default.
- W4375846719 hasConceptScore W4375846719C2777938653 @default.
- W4375846719 hasConceptScore W4375846719C2778461978 @default.
- W4375846719 hasConceptScore W4375846719C2779878957 @default.
- W4375846719 hasConceptScore W4375846719C41008148 @default.
- W4375846719 hasConceptScore W4375846719C500558357 @default.
- W4375846719 hasConceptScore W4375846719C71924100 @default.
- W4375846719 hasConceptScore W4375846719C77088390 @default.
- W4375846719 hasConceptScore W4375846719C98274493 @default.
- W4375846719 hasLocation W43758467191 @default.
- W4375846719 hasOpenAccess W4375846719 @default.
- W4375846719 hasPrimaryLocation W43758467191 @default.
- W4375846719 hasRelatedWork W2367140913 @default.
- W4375846719 hasRelatedWork W2410882444 @default.
- W4375846719 hasRelatedWork W2437485626 @default.
- W4375846719 hasRelatedWork W2998313243 @default.
- W4375846719 hasRelatedWork W3158067688 @default.
- W4375846719 hasRelatedWork W3187863152 @default.
- W4375846719 hasRelatedWork W3207614484 @default.
- W4375846719 hasRelatedWork W3216505685 @default.
- W4375846719 hasRelatedWork W4255572155 @default.
- W4375846719 hasRelatedWork W4308939583 @default.
- W4375846719 isParatext "false" @default.
- W4375846719 isRetracted "false" @default.
- W4375846719 workType "article" @default.